LGALS9 and neoplasm: Gal-9 was identified as the first TIM-3 ligand and to date mediates many of the immunosuppressive effects of TIM-3, with high expression observed in immune system tissues such as the bone marrow, thymus, lymph nodes, and spleen, as well as being actively secreted by tumor cells [142,143,144].